Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Promis is compared to competition in this article
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(10)
•••
Comment by Lynx9on Aug 08, 2022 12:14pm
174 Views
Post# 34878979

RE:Promis is compared to competition in this article

RE:Promis is compared to competition in this article After suffering, not once but twice, the reading of this article I have to say in as much certainly as I can embarrassing say - this was way over my head. The only paragraph that made any sense to me was the very last paragraph in the ProMIS section at the end of the article, Michal Jorrin, aka "Doc Gumshoe" a medical writer found what ProMIS is working on somewhat positive and will be watching. Misfolded poteins are real.  LMAO That article will take a few more years of univercity for me to come anywhere near understanding but suffering through it to the last paragraph was satisfying and encouraging that what Promis is doing is actually getting noticed. Finally!

Article contents
Taurx - private corp
Anavex
Viagra and Dementia
Cassava
Inmune Bio
ProMIS

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities